NOXXON Pharma N.V. announced that new data from the ongoing Phase 1/2 GLORIA trial with NOX-A12 and radiotherapy in brain cancer (glioblastoma multiforme, GBM) were presented at the Society for Neuro-Oncology (SNO) Annual Meeting. The presentation was held by Frank A. Giordano, M.D., Director and Chair of the Department of Radiation Oncology, University Hospital Bonn, Germany, and lead investigator of the ongoing GLORIA study. The oral presentation, entitled ?CXCL12 inhibition in MGMT unmethylated glioblastoma - results of an early proof-of-concept assessment in the multicentric phase I/II GLORIA trial?, included results from 9 chemotherapy refractory (MGMT promoter unmethylated) patients participating in the proof-of-concept study on CXCL12 inhibition during and after radiotherapy of glioblastoma. Eight of 9 patients (89%) receiving NOX-A12 showed reductions in tumor size (2 patients with objective responses [>50% reduction] and 6 patients with stable disease [<50% reduction], while one patient progressed. These results compare favorably with historic patient outcomes from a matched cohort that received standard of care, where only 1 out of 13 patients (8%) showed a reduction in tumor size with an objective response and 12 patients? tumors progressed. Also, data from tissue analysis of a patient on NOX-A12 therapy shows a significant reduction of the NOX-A12 target, CXCL12, on tumor blood vessels, a significant decrease in tumor cell proliferation and an increase in tumor infiltration of activated killer immune cells. Interestingly and very importantly, such benefits were observed across all available tumor tissue and not only in small subsections. These benefits are strongly supportive of the dual mechanism of action of NOX-A12: inhibiting repair of blood vessels damaged by radiotherapy; promoting of immune-response. This dual mechanism of action could prove transformational since this is not consistently observed in historical samples including patients treated with immune checkpoint inhibitors.